Ocrevus

Adult patients w/ relapsing forms of multiple sclerosis w/ active disease defined by clinical or imaging features. Early primary progressive multiple sclerosis w/ imaging features inflammatory-activity characteristic.

IV Adult Premed for infusion-related reactions (IRR): Methylprednisolone (or an equiv) 100 mg IV approx 30 min prior to each infusion; antihistamine (eg, diphenhydramine) approx 30-60 min prior to each infusion. May consider an antipyretic (eg, paracetamol) approx 30-60 min prior to each infusion. Initial dose: 600 mg as 2 separate IV infusions [1st as 300 mg in 250 mL at a rate of 30 mL/hr; 2nd (2 wk later) as 300 mg in 250 mL at a rate of 30 mL/hr]. May increase infusion rate to 30 mL/hr increments every 30 min to a max of 180 mL/hr. Give each infusion over approx 2.5 hr. Subsequent doses: 600 mg IV infusion as single dose every 6 mth; Option 1: 600 mg in 500 mL at a rate of 40 mL/hr. May increase infusion rate to 40 mL/hr increments every 30 min to a max of 200 mL/hr. Give each infusion over approx 3.5 hr; Option 2: 600 mg in 500 mL at a rate of 100 mL/hr for the 1st 15 min. Increase infusion rate to 200 mL/hr for the next 15 min, to 250 mL/hr for the next 30 min & to 300 mL/hr for the remaining 60 min. Give each infusion over approx 2 hr. Patient experiencing mild to moderate IRR Reduce rate to ½ at the onset of the reaction & maintain reduced rate for at least 30 min, may increase infusion rate if tolerated.

Hypersensitivity. Severe active infection until resolution. Patients w/ severely immunocompromised state.

Immunosuppressants

L04AG08 - ocrelizumab ; Belongs to the class of monoclonal antibodies. Used as immunosuppressants.

POM